Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Shattuck Labs, Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05275439CT.gov Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| sl-172154 (this asset) | Shattuck Labs, Inc. | P1 | C · 37 |
| Cytarabine | The First Affiliated Hospital of Soochow University | P4 | BB |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Nivestim | City of Hope Medical Center | P4 | BB |
| Romidepsin | Sawa Ito, MD | P4 | BB |
| Fludarabine | City of Hope Medical Center | P4 | BB |
| Daunomycin | OHSU Knight Cancer Institute | P3 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
+42 more in the Myelodysplastic Syndrome cohort
Other indications for sl-172154
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P1 | CCC · 50 |
| Fallopian Tube Carcinoma | — | P1 | CC · 46 |
| Fallopian Tube Cancer | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. sl-172154 in Myelodysplastic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sl-172154-myelodysplastic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →